Search News Archives
Follow us on
Conferences | Events

Media Partners

 

New Diagnostic Test Helps Hospitals More Quickly Identify and Treat Emerging Antibiotic-Resistant Bacteria

publication date: Dec 6, 2018
 | 
author/source: Becton Dickinson and Company

Diagnostic-Test-Helps-Hospitals-Identify-Treat-Emerging-Antibiotic-Resistant-Bacteria


BDBD, a leading global medical technology company, has announced the U.S. Food and Drug Administration 510(k) clearance of the BD Phoenix™ CPO detect test, which will allow hospitals to identify infections caused by carbapenemase-producing organisms (CPOs).

The test may help hospitals contain the spread of antimicrobial resistance (AMR) by shortening the time it takes to detect CPOs, thereby enabling the earlier implementation of infection control procedures and the initiation of appropriate antibiotic therapies designed for treating these infections.

According to the Centers for Disease Control and Prevention (CDC), CPOs, specifically Carbapenem-resistant Enterobacteriaceae (CRE), represent a prominent AMR threat to public health because these dangerous microbes are often resistant to nearly all available antibiotics.1 These organisms are also on the World Health Organization (WHO) priority pathogen list as critical threats to public health.2 Reported rates of mortality associated with certain CPO infections vary widely, from 22 percent to 72 percent.3 Once identified, rapid implementation of infection prevention measures are needed to prevent further transmission of these organisms and for appropriate patient management".4-5

"The BD Phoenix™ CPO detect test is a completely new type of phenotypic test, and its range of automation and diagnostic capabilities is unmatched by all other currently marketed tests," said Kenneth S. Thomson, PhD, FIDSA, FAAM, FASM clinical professor of Pathology and Laboratory Medicine, University of Louisville School of Medicine. "It represents a significant advance in meeting an important clinical need for rapid detection of CPOs."

The BD Phoenix™ CPO detect test, currently available in two configurations as part of the BD Phoenix™ automated microbiology system, detects CPOs and depending on configuration, can provide the Ambler classification of the enzyme produced to help inform clinicians in appropriate therapy selection. The test is included on BD Phoenix™ gram-negative panels, allowing hospital labs to offer it as part of routine antibiotic susceptibility testing.

The test streamlines laboratory workflow by routine, concurrent testing of CPO and susceptibility to one panel.  Conventional phenotypic methods for CPO detection can take up to 96 hours, whereas the BD Phoenix™ CPO detect test can accurately detect CPOs in under 36 hours. 

"The BD Phoenix™ CPO detect test gives laboratories an accurate and cost-effective method to rapidly identify CPOs and support patient management," said Steve Conly, vice president, general manager of Microbiology for BD Diagnostic Systems. "Along with the BD Phoenix™ M50 instrument, this automated first-to-market, phenotypic test to detect CPOs, using the BD Phoenix™ system, expands the BD portfolio of solutions for identification and antimicrobial susceptibility testing and is another example of the company's commitment to providing solutions that help address the global burden of AMR."

All versions of the BD Phoenix™ CPO detect test will be available beginning in January 2019.

 

more about the BD Phoenix™ systems

more from BD



If you have not logged into the website then please enter your details below.



 

Popular this Month

 

Chromatography in Cannabis Testing

 

New Catalogue of Infectious Disease Antibodies and Antigens

 

Acquisition of B&W Tek takes Metrohm’s Spectroscopy Portfolio to the Next Level

 

Gilson announce the release of the extended mass range VERITY® 1910 MS Detector

 

NanoFCM Opens European Office and Centre of Excellence for Scientific Application Support

 

Hitachi High-Technologies Launches Two New Scanning Electron Microscopes

 

Discovery Park & MedCity to Partner on Prestigious Angels In MedCity Programme

 

Merck Lectureship 2019 Awarded to Susumu Kitagawa

 

BioCity Invests in Carbon Recycling Start-Up, Deep Branch Biotechnology

 

Agilent Announces Unique Portfolio to Advance Immunotherapy

 

 


 

Can't find what you are looking for?

Search by company or by product


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd